Heart Failure Drug Shows Promise in Reducing Chemotherapy-Induced Heart Damage

**The American Heart Association's Scientific Sessions 2024** unveiled promising preliminary findings on the heart-failure drug *sacubitril-valsartan*, which appears to reduce chemotherapy-induced heart damage. Anthracyclines, a common chemotherapy class for cancers like breast cancer and leukemia, pose a risk of cardiomyopathy, a form of cardiotoxicity resulting in heart muscle damage. The SARAH trial analyzed 114 high-risk patients undergoing chemotherapy with anthracyclines, revealing a 77% reduction in heart damage risk when treated with sacubitril-valsartan versus placebo. The medication also improved *global longitudinal strain* (GLS), a heart contractility marker, highlighting its protective potential. Despite its promising results, the study, conducted in Brazil, had limitations like a lack of diverse demographics and a focus solely on high-risk patients. Further research is necessary to assess broader applicability and long-term effects.